BRAF and cancer: We also observed several mutations in the MAP kinase signaling pathway (14% of tumors), involving KRAS, NRAS, BRAF, and MAP2K1 oncogenes across multiple cancer types including hematologic, lung, ovarian, duodenal, biliary, and colorectal (Figure 4, Table 2, Supplementary Table 7).